Truist Securities Maintains Hold on Immunovant, Raises Price Target to $33
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $30 to $33.
Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $30 to $33.